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Fifty-two percent were hospitalized during the last 2 years. Due to cost, 9% had a
specific medical problem but did not visit a doctor and 9% skipped or did not get a
medical test, treatment, or follow-up, recommended by a doctor. The respondent
with family spent on average 667;- € (highest in UK: 1.357,- €) on medical treatment
not covered by insurance. CONCLUSIONS: These interim survey results point to a
patient population (SPAF) under challenging conditions requiring numerous re-
sources. Future research with extended respondent numbers needs to be analyzed
to allow robust and clear recommendations.
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OBJECTIVES: To evaluate and compare patient satisfaction with stroke prevention
in atrial fibrillation (SPAF) in Europe. Secondary objective is to investigate and
compare the influence of health care systems on patient satisfaction. Interim re-
sults are presented to initiate discussions and guide analysis for the main survey.
METHODS: A survey based on the Commonwealth Fund Survey (2008) for chroni-
cally ill adults is applied to patients with SPAF, with few disease-specific adjust-
ments made. The survey is carried out with structured randomized anonymous
telephone interviews in France, Germany, Italy, Spain and UK, screening for re-
spondents with AF aged over 18. Total pilot sample size is 152 respondents, evenly
divided per country.RESULTS:The pilot results indicate differences to other chron-
ically ill patients as well as country variations. Mean age of respondents was 67,
50% were female. For 12%, test results, medical records, or reasons for referrals,
were not available at the time of their scheduled doctor’s appointment. Twenty
percent had doctors recommending treatment that the respondents thought had
little or no health benefit. 30% felt often or sometimes during the past 2 years that
their time was wasted because of poorly organized medical care. 35% had a doctor
who sometimes, rarely or never encouraged them to ask questions. 29% had a
doctor who sometimes, rarely or never gave them clear instructions about symp-
toms and when to seek further care or treatment. 39% of the respondents had
sometimes, rarely or never (21%) a regular doctor or someone in their doctor’s
practice to help coordinating or arrange the care they received from other doctors
and places. CONCLUSIONS: The interim survey results implicates that there is
room for improvement of the health care systems, the organization of medical care
and for communication. Future research with extended respondent numbers
needs to be analyzed to allow robust and clearer recommendations.
PCV114
PREFERENCES FOR COMMUNICATION OUTCOMES FOLLOWING A STROKE
Davies (on behalf of the ACT NoW study team) LM
University of Manchester, Manchester, UK
OBJECTIVES: Communication impairment after stroke has wide-ranging impacts
on everyday activities and social participation. Following stroke, there are waiting
lists of upto 6 months for National Health Service (NHS) speech and language
therapy (SLT). Objectives were to estimate the willingness of participants to wait
for SLT for communication impairment. METHODS: A binary, forced choice, dis-
crete choice experiment (DCE) measured preferences. Attributes, levels and de-
scriptions were derived from COAST, a validated communication impairment spe-
cific measure developed with service users. Factor analysis and expert review
identified four (5-level) items for the DCE (impact of communication impairment
on: social/family life; involvement in interests/hobbies; daily activities; worry and
unhappiness; waiting time). A fractional factorial design and modulo arithmetic
identified 25 choice sets. A random sample of 4000 members of the general public
was invited to participate by post. The design had 89% efficiency for a linear addi-
tive, main effects model, with all five attributes. RESULTS: A total of 278/4000
people participated. All the attributes were important contributors to the prefer-
ences of participants (p0.01). Ability to communicate with family and friends was
the most important attribute. Participants were willing to wait longer than 6
months for improvements (8-37 months) in each attribute. Participant character-
istics did not affect the results. CONCLUSIONS: Participants may be willing to wait
longer than one year for treatment that improves their ability to communicate and
the impact that this has on their lives. This is longer than the maximum waiting
time included in the survey, and questions government policy to target waiting
times to improve health care. Younger people are willing to wait for longer for
therapy than older people. A number of assumptions were made in the design and
conduct of the DCE survey. Combined with the low response rate (7%), the results
are only indicative of preferences. Further surveys are merited.
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OBJECTIVES: To investigate whether patient reported outcomes could detect ad-
verse event differences between cholesterol lowering agents “statins” and patients
could recall enough information to assess the differences. METHODS: In this eval-
uation, PROBE (patient reported outcomes based evaluation) methodology consist-
ing of a web-based system supplemented by telephone reporting was used to col-
lect naturalistic data from people who were taking or about to start “statin”
therapy. People were recruited through internet pay per click advertising, social
networking sites and search engine optimisation. Data collection was a one off
questionnaire. Data included baseline demographics, therapy name, dose, choles-
terol level before and after treatment, any side effects and action taken in response
to side effect. RESULTS:A total of 679 recipients participated in the evaluation. 49%
of participants were male with 43% aged between 41-60 and 52% between 61 -80.
Overall, 336 (52%) of respondents felt they had experienced a side effect since
commencing “statin” therapy with an average of 5 side effects per person. 121 (18%)
people reported that they required treatment with respect to the side effect, the
commonest report being muscle pain in the arms or legs (28% of patients account-
ing for 39% of all side effects). Interestingly, 24% of people on atorvastatin (mean
dose 26mg) required treatment in relation to their side effect(s) as compared to 19%
on simvastatin (mean dose 29mg). 64% of people could recall their cholesterol
before starting therapy and 94% supplied a meaningful figure. CONCLUSIONS: This
evaluation shows that the PROBE methodology quickly and simply captured pa-
tient reported outcome information on adverse events and patient actions in a
population taking cholesterol lowering therapy. Half the population receiving “st-
atins” reported a side effect and 18% required a medical intervention in relation to
their side effect(s).
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OBJECTIVES: This study investigates stroke risk and the association with health-
related quality of life (HRQoL), and resource use among diagnosed atrial fibrillation
(AF) patients. METHODS: The study included data from the EU 2010 (N57,805)
National Health and Wellness Survey, a self-administered, internet-based ques-
tionnaire from a demographically representative sample of adults (aged 18) in
5EU. Stroke risk was assessed with CHA2DS2-VASc, an index summing the pres-
ence of congestive heart failure, hypertension, age  75 (2 points), diabetes melli-
tus, previous stroke/transient ischemic attack (2 points), vascular disease, age 65-
74, and female gender. Low- (CHA2DS2-VASc 0), moderate- (1), and high- (2) risk
patients reported on measures of HRQoL (mental (MCS), physical component sum-
mary (PCS) and SF-6D (health utility) scores from the SF-12v2), and health care
resource use. RESULTS: Among 479 diagnosed AF respondents (prevalence of
0.93%), 15.1% were low, 27.9% moderate, and 57.0% high risk for stroke. Significant
differences exist in the use of anticoagulant medication for stroke prevention
among low- (38.9%) vs. moderate- (54.9%), and high- (59.8%) risk patients, p0.05.
High-risk patients reported significantly lower levels of HRQoL relative to low-risk
patients (PCS: 37.1 vs. 41.3; Utilities: 0.65 vs. 0.70, p.05). The number of hospital-
izations and physician visits in the past 6 months were also significantly higher for
high-risk patients compared with both low-risk and moderate-risk patients (hos-
pitalization: high- (0.43) vs. moderate- (0.26) and low-risk (0.14), p0.05)
CONCLUSIONS: In 5EU, 40% of AF patients at high-risk of stroke are not taking
anticoagulant medication. Being high-risk for stroke can be a substantial burden on
AF patients, reducing their HRQoL, after accounting for demographics, patient
characteristics, and comorbidities. Increased number of hospitalizations and phy-
sician visits suggests that these AF patients can place a substantial burden on the
healthcare system. There remains an unmet need for enhanced treatment of high-
risk AF patients.
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OBJECTIVES: To compare clinical and patient-reported outcomes of OM/AML/HCT
triple combination of different dose strengths with that of respective double com-
bination in hypertensive patients. METHODS: The study (CS8635-A-E302) was a
randomised, double-blind, parallel-group study, multi-centre, European, phase III
clinical trial evaluating the efficacy and safety of co-administration of triple com-
binations OM/AML/HCT directly compared with the corresponding double combi-
nation of OM/AML in subjects with hypertension. The following five pairwise treat-
ment group comparisons were considered after 10 weeks: A) OM20/AML5/
HCT12.5mg vs. OM20/AML5; B) OM40/AML5/HCT12.5mg vs. OM40/AML5; C) OM40/
AML5/HCT25mg vs. OM40/AML5; D) OM40/AML10/HCT12.5mg vs. OM40/AML10; E)
OM40/AML10/HCT25mg vs. OM40/AML10. Primary clinical outcome was the re-
sponder rate defined as percentage of subjects achieving blood pressure goal
(140/90 mmHg; 130/80 mmHg for subjects with diabetes, chronic renal disease,
or chronic cardiovascular disease). The number-needed-to-treat (NNT) was calcu-
lated. Patient reported outcomes (PRO) were recorded on two quality-of-life (QoL)
instruments, EQ-5D and MINICHAL. RESULTS: Overall, 2690 patients (mean age:
56.510.5 years; 53.6% female) were followed over 10 weeks, balanced in each
treatment group. Responder rate was higher in triple treatment groups compared
to respective dual combination: A) 53.0% versus 42.7%, p0.05, NNT 10 patients; B)
52.4% versus 46.4%, NNT 17 patients; C) 58.8% versus 46.4%, p0.05, NNT 9 patients;
D) 56.5% versus 49.6%, NNT 15 patients; E) 53.9% versus 49.6%, NNT 23 patients.
Whereas patients reported statistically significant intra-individual improvements
for most of the treatment regimens (mean improvement ranged from 0.007 to 0.026
(EQ-5D utility score) and from -1.2 to -1.7 (MINICHAL), the 10-week change in QoL
was not significantly different between treatment groups of triple and the respec-
tive dual combination. CONCLUSIONS: Overall, responder rates are superior in
patients receiving triple combination OM/AML/HCT in comparison to the respec-
tive dual combination OM/AML. Although the triple combination contains a further
agent this had no negative impact on QoL.
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